Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Aradigm Corporation
The company, which has treatments in the clinic for CLN2 Batten disease and APOE4-associated Alzheimer’s disease, is developing AAV-mediated gene therapies designed for safer outcomes.
The diuretic bumetanide had shown potential to improve the core symptoms of children and adolescents with autism in small studies but has failed to demonstrate any sign of effectiveness in two late-stage trials.
Intas and Arecor have struck an exclusive licensing deal that will see the pair use Arecor’s proprietary Arestat formulation technology to develop value-added medicines, in particular for use outside of the hospital setting.
Immersive technologies are becoming a reality in the OR. In Vivo explores the future of surgery, profiling innovators of augmented reality technologies and exploring the promise and challenges surrounding robotic surgery as companies try to take technologies to the next level.
- Medical Devices
- Drug Delivery